The company hopes to push the rare-disease treatment toward FDA approval next year. Four months after ditching its lead drug, ...

U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what ...

The acquisition will also help the South Florida company expand its presence in Europe. PharmaLogic Holdings Corp, a manufacturing organization specializing in radiopharmaceuticals, will acquire a ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an ...

During a recent panel discussion sponsored by Purdue University, industry leaders explain how the technology is revolutionizing drug development and production ...

Plus: Comcast rolls out small-business assistance; Richie Neal takes Trump to task for tariff policies; Healey rolls out new ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...